Immune Design Corp.
IMDZ
IMDZ was delisted on the 1st of April, 2019.
65 hedge funds and large institutions have $147M invested in Immune Design Corp. in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 22 reducing their positions, and 6 closing their positions.
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
14% more capital invested
Capital invested by funds: $128M → $147M (+$18.2M)
7% more funds holding
Funds holding: 61 → 65 (+4)
3.47% more ownership
Funds ownership: 51.56% → 55.03% (+3.5%)
0% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$8.95M |
| 2 |
DAM
Doheny Asset Management
Los Angeles,
California
|
+$6.02M |
| 3 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
+$1.16M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$857K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$813K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
ProQuest Associates IV
Naples,
Florida
|
-$5.41M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.64M |
| 3 |
Millennium Management
New York
|
-$1.41M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$556K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$468K |
IMDZ Hedge Fund Activity: Q3 2017 in Review
65 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Immune Design Corp. (IMDZ) for Q3 2017, worth a combined $147M — up 14% from $128M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new IMDZ positions and 6 closed out — a net gain of 5 holders — while 22 added to existing stakes and 22 trimmed.
The largest buyer was Bain Capital Public Equity Management, adding an estimated $8.95M. The largest seller was ProQuest Associates IV, cutting an estimated $5.41M.
- 65 institutional investors held Immune Design Corp. (IMDZ) as of Q3 2017, up from 61 in Q2 2017.
- Funds reported $147M of Immune Design Corp. stock for Q3 2017, up 14% quarter-over-quarter.
- 11 funds opened new Immune Design Corp. positions in Q3 2017 and 6 closed out, a net change of +5 holders.
- The largest Immune Design Corp. buyer in Q3 2017 was Bain Capital Public Equity Management, an estimated $8.95M added.
- The largest Immune Design Corp. seller in Q3 2017 was ProQuest Associates IV, an estimated $5.41M sold.
Based on aggregated 13F filings for Q3 2017.